Rationale P-glycoprotein (P-gp) plays an important role in the efflux of drugs from the brain back into the bloodstream and can influence the pharmacokinetics and pharmacodynamics of drug molecules. To our knowledge, no studies have reported pharmacodynamic effects of any antidepressant drug in the P-gp knockout mice model. Objective The aim of this study was to investigate the enantiomeric venlafaxine and metabolite concentrations in serum and brain of abcb1ab (−/−) mice compared to wildtype mice upon chronic dosing, and to assess the effect of venlafaxine treatment on open-field behavior. Methods P-gp knockout and wild-type mice received two daily intraperitoneal injections of venlafaxine (10 mg/kg) over ten consecutive days. Locomotor and rearing activities were assessed on days 7 and 9. After 10 days, drug and metabolite concentrations in brain and serum were determined using an enantioselective LC/MS/MS method.
Introduction
Depression is a common and significant public health problem, and the leading cause of suicide worldwide (Kessler et al. 2009; Moussavi et al. 2007 ). Pharmacological treatment is one of the cornerstones in clinical practice, but however, it is well known that the result of antidepressant therapy can vary within a population. One factor contributing to this might be the ability of the drug to cross the blood-brain barrier (BBB). Two important functions of the BBB are protection of the brain against potentially toxic substances and maintenance of a constant internal environment, which is of primary importance for optimal neuronal functioning of the brain. The BBB expresses transport proteins, which actively transport their substrates out of the brain back into the blood circulation (Ballabh et al. 2004) . One of the most studied transport proteins is P-glycoprotein (P-gp) (Cordon-Cardo et al. 1989; Thiebaut et al. 1987) , which belongs to the highly conserved superfamily of ATPbinding cassette (ABC) transporter proteins (Ambudkar et al. 1999) . The importance of P-gp in the transport of drugs over the BBB has been studied using abcb1ab knockout mice (Schinkel et al. 1994 , thus providing a unique and valuable pharmacological tool.
A well-known problem in modern psychopharmacology is the existence of chiral drugs composed of enantiomers, which may differ in their pharmacokinetic and pharmacodynamic properties (Baker and Prior 2002; Baumann et al. 2002; Howland 2009 ). One example of such a drug is venlafaxine, which inhibits serotonin more than noradrenaline reuptake and slightly inhibits dopamine reuptake (Muth et al. 1986) . Venlafaxine is used for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder (Stahl et al. 2005) . Venlafaxine exists as a racemic mixture of the R-(−)-and S-(+)-enantiomeric forms in equal amounts, both of which inhibits monoamine reuptake (Muth et al. 1986 ). However, the R-enantiomer is a potent inhibitor of both serotonin and noradrenaline reuptake, whereas the S-enantiomer is more selective in inhibiting serotonin reuptake (Holliday and Benfield 1995; Muth et al. 1986) . Venlafaxine is mainly metabolized by the cytochrome P450 (CYP) enzyme CYP2D6 to its major active metabolite O-desmethylvenlafaxine (Odm-venlafaxine) and to its two minor metabolites, N-desmethylvenlafaxine (Ndm-venlafaxine) and N,O-didesmethylvenlafaxine (Ddm-venlafaxine) (Muth et al. 1986 (Muth et al. , 1991 .
Several pharmacokinetic studies have been published using the abcb1ab knockout mouse model, and P-gp has been shown to significantly limit brain entry of a wide variety of drugs, including venlafaxine (Doran et al. 2005; Kirschbaum et al. 2010; Uhr et al. 2000 Uhr et al. , 2008 . Using this animal model, we have recently shown that P-gp decreases the brain penetration of the S-and R-enantiomers of venlafaxine and its metabolites after an acute drug challenge ). However, no enantiomeric pharmacokinetic data are available following chronic drug administration. Further, to our knowledge, no studies have reported pharmacodynamic effects of any antidepressant drug to P-gp deficient mice and its wild-type controls. The open-field test is the method of choice for analyzing an animal's spontaneous behavior in response to a novel environment (Avgustinovich et al. 2000; Gershenfeld and Paul 1997) . Following a drug challenge, this test in rodents gives hints for main clinical effects (Apelqvist et al. 1999; Kennett et al. 1987; Kugelberg et al. 2002 Kugelberg et al. , 2005 Kugelberg et al. , 2006 .
To obtain results that are more closely related to the clinical situation, we decided to follow up our previous acute study ) by chronic treatment with venlafaxine in the P-gp knockout mouse model. The aims of the study were to investigate: (1) the distribution of the enantiomers of venlafaxine and its three major metabolites in serum and brain after 10 days of drug administration; and (2) the effect of chronic drug treatment on open-field behavior.
Materials and methods

Animals
Male abcb1ab (−/−) mice (mean weight, 35 g) on a FVB/N background (Taconic's Germantown, NY, USA) and male FVB/N wild-type mice (abcb1ab (+/+)) (mean weight, 31 g) were housed in groups of five in cages with sawdust bedding under normal indoor temperature and humidity, and maintained on a 12-hour light-dark cycle, with food and water ad libitum. All experiments were conducted in accordance to the European Guide for the Care and Use of Laboratory Animals and approved by local authorities.
Drugs and chemicals
Racemic venlafaxine-HCl (Wyeth-Ayerst Research, Rouses Point, VT, USA) was dissolved in 0.9% NaCl and administered intraperitoneally (i.p.). All other chemicals were in the purest grade commercially available.
Experimental design
For the pharmacokinetics, venlafaxine was administered to abcb1ab (−/−) knockout (n=10) and abcb1ab (+/+) FVB/N wild-type (n=10) mice by daily i.p. injections during a brief anesthesia with isoflurane (Forene®, Abbott GmbH & Co. KG, Wiesbaden, Germany). The concentration used was 10 mg/kg body weight, and the volume injected twice daily (8:00 a.m. and 8:00 p.m.) was 1 mL, giving a total dose of 20 mg/kg/day. The choice of dosage regimen was based on previous pharmacokinetic Karlsson et al. 2010 ) and pharmacodynamic (Kumar et al. 2010; Takeuchi et al. 2010 ) studies, in which doses within the range 5-20 mg/kg were used. Ten days following drug administration, the knockout and wild-type mice were anesthetized with isoflurane and decapitated 1 h after the last injection. Serum and brain samples were then collected and frozen at −70°C until further analysis of drug and metabolite concentrations (for details, see below).
For the pharmacodynamics, the number of animals was extended. Venlafaxine was administered to abcb1ab (−/−) knockout (n=16) and abcb1ab (+/+) FVB/N wild-type (n=15) mice by daily i.p. injections as described above. Control mice of each genotype (knockout n=14 and wildtype n=10) were injected with saline instead of venlafaxine. Behavioral testing was performed 7 and 9 days after the start of the drug administration (for details, see below).
Behavioral tests
Exploratory locomotion/activity in mice was assessed in an open-field paradigm. The test arena consisted of dark-gray plastic and measured 60×60×35 cm. The arena was virtually divided in several parts, corners with 15×15 cm, corridors near the wall with 8 cm width and a center-square with again 15×15 cm. That allows, in addition, division of the floor of the arena into two similar large areas a peripheral (corners and walled part) and central (center area and rest). The mouse was allowed to explore the arena for 10 min. Track path was subsequently analyzed by the automated system for the following parameters: distance traveled (cm), time spent in the various parts of the arena and the number of rears. Behavioral testing was performed 30 min after drug injection on days 7 and 9. All behavioral tests were conducted between 9:00 a.m. and 2:00 p.m. The hardware consisted of an IBM-type computer, combined with a video digitizer and a CCD video camera (Panasonic, CCTV Camera WVBP330/GE, Suzhou, China). The software used was EthoVision® release 3.1 (Noldus Information Technology, Utrecht, The Netherlands).
Drug analysis
The concentrations of the S-and R-enantiomers of venlafaxine and its metabolites in serum (nmol/L) and brain homogenate supernatant (pmol/g≈nmol/L) were determined by using a liquid chromatography tandem mass spectrometry (LC/MS/MS) method as described previously Kingbäck et al. 2010) . Briefly, the whole brain samples (mean weight, 400 mg) were homogenized with a sonifier (Sonics VibraCell VC 130; Chemical Instruments AB) in 2 mL Milli-Q water and centrifuged at 2000 g for 20 min. Venlafaxine, Odm-venlafaxine, Ndm-venlafaxine, and Ddm-venlafaxine were extracted from 0.2 mL serum and 0.2 mL brain homogenate supernatant with solid-phase extraction on Isolute C8 columns 100 mg (International Sorbent Technology Ltd). After elution and evaporation, the samples were redissolved in 50 μL of the mobile phase (tetrahydrofuran:ammonium acetate, 10 mM, pH 6; 10:90v/v) before the analysis. The LC/MS/MS system consisted of an Acquity liquid chromatography system (Waters) and an API 4000 tandem quadrupole instrument, equipped with an electrospray interface (TURBO V™ source, TurbolonSpray® probe) operating in positive ion mode (Applied Biosystem/ MSD Sciex). Chromatographic separation was performed on a Chirobiotic-V column (5μm particle size, 250×2.1 mm; Astec/Supelco) protected with a 5μm in-line filter (VICI AB Int.) at a mobile phase flow rate of 0.2 mL/min. The column was kept at 10°C using a Jones Chromatography Model 7955 column chiller/heater. Multiple reaction monitoring (MRM) of the most abundant transitions originating from product ions of the protonated molecular ions was used for quantification. The data were processed using Analyst 1.4.2 software (Applied Biosystem/MSD Sciex). The limit of quantification was 0.5 nmol/L for the enantiomers of venlafaxine and Odm-venlafaxine, and 0.25 nmol/L for the enantiomers of Ndm-venlafaxine and Ddm-venlafaxine.
Extraction recoveries and matrix effects for the brain samples were investigated in the same way as previously described for plasma (Kingbäck et al. 2010) . The extraction recovery in brain homogenate supernatant was determined by comparing extracted spiked blank samples with unextracted reference samples prepared at the same concentrations. Matrix effects were evaluated by comparing the concentrations found of known amounts of working standards with those measured in control brain homogenate supernatant spiked with the same amount of analytes before or after extraction. Brain samples at two different concentration levels (100 and 1000 nmol/L for the enantiomers of venlafaxine and Odm-venlafaxine; 50 and 500 nmol/L for Ndm-venlafaxine and Ddm-venlafaxine) were analyzed. The mean extraction recoveries for the enantiomers of venlafaxine and its metabolites ranged between 75-91% and 74-93%, respectively. The matrix effect data for venlafaxine and metabolites were between 99-105% and 80-88%, respectively, indicating no severe matrix effects.
Statistical analysis
Data are expressed as means±the standard error of the means (SEM). Pharmacokinetic data were analyzed by a two-tailed Student's t-test for unpaired observations using StatView® for Windows Version 5.0 (SAS® Institute Inc., Cary, NC; USA). Behavioral data were analyzed by analysis of variance (ANOVA) followed by a post hoc t-test using SPSS® for Windows Version 12.0 (SPSS Inc., Chicago, IL, USA). For all comparisons p values <0.05 were considered statistically significant.
Results
Concentrations of the enantiomers of venlafaxine and metabolites
The total (S+R) concentrations, the concentrations of the Sand R-enantiomers and the S/R concentration ratios of venlafaxine and its metabolites are displayed in Table 1 . In the brain, the S-and R-enantiomeric concentrations of venlafaxine were found to be 1.6 and 2.4 times higher in the abcb1ab knockout mice as compared to the wild-type mice, respectively (p<0.0001). For the metabolites, the Sand R-enantiomeric concentrations were 2.1 and 2.1 times higher for Odm-venlafaxine, 3.2 and 4.5 times higher for Ndm-venlafaxine and 2.0, and 2.1 times higher for Ddmvenlafaxine in the knockout mice than in the wild-type mice, respectively (p<0.0001). No significant differences were observed in the serum S-and R-enantiomeric concentrations of the knockout mice as compared to the wild-type mice, with one exception for R-venlafaxine (p=0.02).
For venlafaxine and Ndm-venlafaxine, the enantiomeric S/R concentration ratios in the brain were 1.02 and 1.35 in P-gp deficient mice, respectively, as compared to 1.40 and 1.87 in wild-type mice, and these differences between the groups were statistically significant (p<0.0001) (Fig. 1) . However, the S/R ratios in the brain for Odm-venlafaxine and Ddm-venlafaxine did not differ between the abcb1ab knockout mice and wild-type mice (1.60 vs. 1.64 for Odmvenlafaxine and 1.99 vs. 2.08 for Ddm-venlafaxine). The serum S/R ratios differed statistically between the groups (p values ranging from <0.05 to <0.001), even though no differences were found in the S-and R-concentrations of parent drug and metabolites with one exception (Rvenlafaxine p<0.05). Furthermore, when comparing the knockout/wild-type ratios for the S-to R-enantiomers of venlafaxine and metabolites in brain, no major differences between the groups were found: 1.8 for S-venlafaxine compared to 2.4 for R-venlafaxine, 2.1 for S-Odmvenlafaxine compared to 2.1 for R-Odm-venlafaxine, and 3.2 for S-Ndm-venlafaxine compared to 4.5 for R-Ndmvenlafaxine.
In mice lacking P-gp, the brain/serum concentration ratio of venlafaxine was significantly higher compared to wildtype mice (p<0.0001) (Fig. 2) . The brain/serum concentration ratios of Odm-venlafaxine, Ndm-venlafaxine, and Ddm-venlafaxine were found to be 1.7-3.2 times higher in the abcb1ab knockout mice as compared to the wild-type mice (p<0.0001, p<0.0001, and p<0.0005) (Fig. 2) .
The metabolite/parent drug (M/P) ratios for Odmvenlafaxine/venlafaxine, Ndm-venlafaxine/venlafaxine, and Ddm-venlafaxine/venlafaxine in serum were similar between the two groups (0.15, 1.87 and 0.02 in knockout mice vs. 0.16, 1.91 and 0.02 in wild-type mice, respectively). In brain, the M/P ratios for Odm-venlafaxine/venlafaxine and Ddmvenlafaxine/venlafaxine were 0.06 and 0.001 in abcb1ab knockout and wild-type mice. The brain M/P ratios for Ndmvenlafaxine/venlafaxine were 0.7 in knockout mice and 0.4 in wild-type mice (p<0.0001).
Open-field behavior
Distance traveled (locomotion) in the open-field arena was analyzed as a general measure of activity, whereas time spent in various zones and number of rears was used as a measure of exploratory activity. There were no differences in general activity (total locomotion) between the groups after 7 days (F (3;51) =2.369; p=0.08) of chronic drug treatment (Fig. 3) . Nine days after treatment, and after having been in the test before, activity appeared significantly different (F (3;51) =4.394; p≤0.01). Post-hoc analysis indicated that this decrease in activity was based on a significant effect (p=0.011) of venlafaxine treatment in wild-type mice. There were no treatment differences in abcb1ab knockout mice (p=0.074) (Fig. 3) .
Investigating exploration by analysis of the time spent in the periphery or central area showed significant treatment effects after 7 and 9 days of drug administration (F (3;51) = 2.716; p≤0.05 and F (3;51) =4.111; p≤0.01, respectively). Post hoc comparisons showed that abcb1ab knockout mice treated for 7 days with venlafaxine spent significantly more time in the central area compared to similar treated wildtype (p=0.031) and untreated abcb1ab knockout mice (p=0.022) (Fig. 4) . After 9 days of chronic treatment, post hoc comparison revealed a significant difference to untreated abcb1ab knockout mice only (p=0.002) (Fig. 4) , indicating that treatment effects in wild-type animals need longer time to emerge. Locomotor activity within the various zones displayed only a significant effect in the periphery 9 days after treatment (F (3;51) =5.043; p≤0.01, 7 days: F (3;51) =1.871; p=0.146) with post hoc comparison showing a clear venlafaxine effect in both genotypes (wildtype p=0.014, abcb1ab knockout p=0.025) (Fig. 3) . Analysis of rears indicated no significant differences in the central area after 7 and 9 days of chronic drug administra- tion (F (3;51) =1.123; p=0.384; F (3;51) =1.413; p=0.250), whereas in the periphery, there was a significant effect after 9 days of treatment (F (3;51) =3.773; p≤0.05), while after 7 days, ANOVA did not show any significance (F (3;51) = 2.415; p=0.077). However, post hoc comparison indicated that after 7 days, abcb1ab knockout mice treated with venlafaxine showed less rears compared to untreated (p=0.034) and wild-type mice (p=0.020) receiving venlafaxine. After 9 days, venlafaxine in both genotypes reduced the number of rears significantly (wild-type p=0.030; abcb1ab knockout p=0.017) again indicating a faster onset of treatment effect in abcb1ab knockout mice (Fig. 4) .
Discussion
The present study was designed to combine pharmacokinetic and pharmacodynamic investigations in the P-gp knockout mouse model after chronic treatment with venlafaxine. To our knowledge, this approach has not previously been applied after administration of any antidepressant drug. We report that the brain concentrations of venlafaxine and its three metabolites were two to four times higher in P-gp deficient mice compared to wild-type controls. Despite these differences, the enantiomeric drug and metabolite dispositions in serum and brain were similar between the two genotypes. The open-field test indicated an impact on exploration-related behaviors in knockout mice, as center activity was increased, and rears were decreased by chronic venlafaxine treatment. P-gp is responsible for transporting a substrate back into the blood, thereby inhibiting the transport of certain substances, including drugs to enter the brain. This means that P-gp may prevent certain drugs from reaching the central nervous system (CNS) in therapeutic doses. Studies have shown that the activity of the gene coding for P-gp, ABCB1, varies between individuals, which means that drug concentrations in the brain is dependent on P-gp levels (Kroetz et al. 2003) . A high level of gene activity may be the reason why a patient does not reach sufficiently high concentrations in the brain, and therefore, may not get the correct effect of the treatment. Several single-nucleotide polymorphisms (SNPs) identified in the human ABCB1 gene have been associated with altered P-gp expression and phenotype (Hoffmeyer et al. 2000; Kim et al. 2001; Tanabe et al. 2001) , and some of the polymorphisms have been connected with antidepressant response (Gex-Fabry et al. 2008; Kato et al. 2008; Nikisch et al. 2008; Uhr et al. 2008) . Accordingly, it is of clinical value to detect whether a particular drug given to treat a CNS disease is a substrate for P-gp. Whereas P-gp is encoded by a single gene in humans (ABCB1), mice have two homologues, the abcb1a and abcb1b genes (Devault and Gros 1990) . To identify which drugs are substrates of P-gp, mice lacking both the abcb1a and abcb1b genes have been used. This animal model shows that antidepressants like citalopram, doxepin, venlafaxine, and paroxetine are substrates of P-gp at the BBB Lagas et al. 2009; . In the present study, venlafaxine was administered for 10 days to investigate the timedependent interaction between the drug and P-gp. Using a stereospecific LC/MS/MS method, we analyzed the enantiomeric concentrations and showed that the separate enantiomers of the parent compound and its three metabolites are substrates of P-gp. This was evidenced by two to four times higher brain concentrations of venlafaxine, Odm-venlafaxine, Ndm-venlafaxine and Ddm-venlafaxine in the abcb1ab (−/−) mice as compared to the abcb1ab (+/+) mice. In a recent study performed by us , where abcb1ab knockout mice received a single i.p. injection of venlafaxine, we measured up to twofold higher brain concentrations of venlafaxine, whereas the brain concentrations of Odm-venlafaxine and Ndmvenlafaxine were two to three times higher than in wildtype mice 1h post dose. In a chronic study by Uhr and coworkers, 1.7-and 4.1-fold higher brain concentrations of venlafaxine and Odm-venlafaxine were observed in abcb1ab knockout mice than in wild-type mice (Uhr et al. 2008) .
The serum and brain concentrations of venlafaxine and Odm-venlafaxine were found to be similar, following both acute ) and chronic drug administration to abcb1ab knockout and wild-type mice. In the literature, little is known about the pharmacological profiles of Odmvenlafaxine and the two other demethylated metabolites, and to our knowledge, no data are available describing the effects of the separate enantiomers. Desvenlafaxine is a newly marketed antidepressant of the serotonin-noradrenaline reuptake inhibitor (SNRI) class. Desvenlafaxine is a synthetic form of the isolated major active metabolite (Odm-venlafaxine) of venlafaxine. According to a product monograph, desvenlafaxine is not a substrate or an inhibitor for the P-gp transporter in vitro (WYETH 2009). Furthermore, the pharmacokinetics of desvenlafaxine is unlikely to be affected by drugs that inhibit the P-gp transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-gp transporter (WYETH 2009). However, in the product monograph, it is not stated in which type of cells these data were obtained. Nevertheless, these findings are not in line with our in vivo results, where major differences in brain concentrations of Odm-venlafaxine between the abcb1ab knockout mice and the wild-type mice were observed. However, other available data from the literature is also inconsistent. For example, studies in Caco-2 cells have given contradicting results for venlafaxine (Ehret et al. 2007; Oganesian et al. 2009 ). The antidepressant drug, citalopram, is another example, where different results have been reported in vitro (Rochat et al. 1999 ) and in vivo Doran et al. 2005) . To study Odm-venlafaxine (desvenlafaxine) and Ndm-venlafaxine separately in our mice model would be of high interest to further elucidate this important issue. The given dose of venlafaxine (20 mg/kg/day) in the present study has previously been estimated to approach the human therapeutic serum level (de Klerk et al. 2009 ). The mean serum levels of venlafaxine were 1,277 and 1,083 nmol/L in knockout and wild-type mice, respectively, which are levels seen in the upper range in therapeutic drug monitoring (TDM) in humans (Reis et al. 2002) . The metabolite/parent drug (M/P) ratios in serum for Odmvenlafaxine/venlafaxine, Ndm-venlafaxine/venlafaxine, and Ddm-venlafaxine/venlafaxine were 0.16, 1.9, and 0.02 in wild-type mice. Comparing these ratios to patients, Reis and coworkers reported mean serum ratios of 5.5, 0.6, and 2.1, respectively (Reis et al. 2002) . However, the interindividual variability showed a wide range (min-max, 0.01-35, 0.01-7.8, and 0.08-30, respectively) . In another TDM study, an Odm-venlafaxine/venlafaxine ratio of 2.5 was reported (Reis et al. 2009 ). Compared to humans, the mice in the present study displayed higher concentrations of Ndm-venlafaxine in relation to Odm-venlafaxine (Odmvenlafaxine/Ndm-venlafaxine ratio, 0.08 in mice and 2.5 in humans) (Reis et al. 2002) . Taken together, there seems to be species differences in the metabolic pattern shown by M/P ratios that needs to be considered when results from different studies are compared. One also has to keep in mind how the drug was administered and the time of sampling in relation to the time when the drug was given. In TDM, trough levels are utilized, which requires blood sampling within a drug specific time interval after dosing and steady state.
In the present study, we separately investigated the disposition of the S-and R-enantiomers of venlafaxine and metabolites in serum and brain. The abcb1ab knockout mice displayed somewhat lower S/R concentration ratios of venlafaxine and Ndm-venlafaxine as compared to the wildtype mice. Also for Odm-venlafaxine, a minor difference in S/R ratios was observed between the groups in serum but not in the brain. However, when comparing the knockout/ wild-type ratios for the S-to R-enantiomers of venlafaxine and metabolites in brain, no major differences between the groups were found. Hence, no major differences in stereoselective disposition of venlafaxine, Odm-venlafaxine, Ndm-venlafaxine, and Ddm-venlafaxine were found in the abcb1ab knockout mice model. For S/R-verapamil, an absence of stereoselective P-gp mediated transport has been reported (Luurtsema et al. 2003; Sandstrom et al. 1998) . It has to be taken into account that we only tested one dose. P-gp might be a saturable transporter, and lower or higher doses of the drug could lead to results that would differ between the groups. P-gp exports antidepressants at different rates, for instance, when comparing the brain penetration for abcb1ab (−/−) to wild-type mice, the ratio for doxepin is low (1.2) ) and for venlafaxine higher (2.0) (present study). Compared to stronger P-gp substrates like digoxine (ratio 19) , the ratios of the antidepressants are quite low but might still be of clinical relevance (Uhr et al. 2008 ).
To our knowledge, pharmacodynamic investigations of venlafaxine or any other antidepressant have not previously been performed in the abcb1ab knockout mouse model. In the literature, only limited data are available, addressing the influence of P-gp on the pharmacodynamics using P-gp knockout mice (Kalvass et al. 2007a, b; Kirschbaum et al. 2008) . In the present study, we investigated the relevance of being a substrate to P-gp in our mouse model by pharmacodynamic investigations in the open-field. The open-field test was chosen to detect several behavioral changes related to both wanted and unwanted effects of the drug. Our results demonstrate that venlafaxine has an impact on open-field behavior, and this is modulated by P-gp activity. The impact on rodent behavior of venlafaxine treatment is in line with the previous investigations of us (Kugelberg et al. 2005; Wikell et al. 2002) and others (Brocco et al. 2002; de Oliveira et al. 2004 ). Behavioral changes indicated an impact on exploration-related behaviors in the open-field (Gentsch et al. 1987; Schmitt and Hiemke 1998; Swiergiel and Dunn 2007) , as center activity was increased and rears were decreased by venlafaxine treatment. Those pharmacodynamic effects were even more pronounced in abcb1ab (−/−) mice 7 days after chronic treatment. Whether the increase in effect size 9 days after chronic drug administration, especially in abcb1ab (+/+) mice, has to be attributed to the time of treatment or a changed ratio between venlafaxine, and its metabolites could not be answered by the present investigation. However, the chronic data revealed constant levels of Odm-and Ndm-venlafaxine, which might contribute to the behavioral changes. Therefore, a pharmacodynamic analysis after pure metabolite treatment is of specific interest to solve those questions.
The strength of the present study is the combination of pharmacokinetic and pharmacodynamic effects of a chronic antidepressant treatment with respect to the impact of P-gp expression. However, there are some limitations in the analysis of the pharmacodynamic data that needs to be addressed. Repeated testing in an open-field setting leads to habituation (Thiel et al. 1999) , which is seen in the present data by reduced overall activity in the test 9 days after treatment. Whether habituation is affected differentially in these genotypes is unknown so far. Similarly, there is only little known about a specific influence of venlafaxine on habituation. However, there are some reports of venlafaxine affecting learning and memory in a positive way (Nowakowska and Kus 2005; Nowakowska et al. 2003) . Thus the more pronounced effects of venlafaxine 9 days after chronic treatment were hardly explained by drugmediated habituation processes.
In conclusion, our findings, along with the previous results, show that P-gp at the BBB plays an important role in limiting brain entry of the enantiomers of venlafaxine and its metabolites. The P-gp substrate properties were reflected in the open-field test where the P-gp deficient mice displayed alterations in exploration activity compared with wild-type controls, following the chronic drug exposure. Taken together, the present pharmacokinetic and pharmacodynamic findings offer the possibility that the expression of P-gp in patients may be a contributing factor for limited treatment response.
